West Pharmaceutical Services (WST) debt: $203M
West Pharmaceutical Services had $203M of long-term debt on Dec 31, 2025, including the part due within a year, up 0.1% from $203M a year earlier.
From West Pharmaceutical Services's filings with the SEC · Read the filing · WST stock page
West Pharmaceutical Services debt by year
#1,407 of 2,129 US companies by debt · See the full ranking
| Year ended | Debt | Change |
|---|---|---|
| Dec 31, 2025 | $203M | +0% |
| Dec 31, 2024 | $203M | -2% |
| Dec 31, 2023 | $207M | -1% |
| Dec 31, 2022 | $209M | -17% |
| Dec 31, 2021 | $253M | – |
Debt of similar companies
Companies in the same industry as West Pharmaceutical Services, by SEC industry code, with the closest debt. Each name opens the same page for that company.
| Company | Debt, latest year | Year ended |
|---|---|---|
| Tandem Diabetes Care | $310M | Dec 31, 2025 |
| Bioventus | $294M | Dec 31, 2025 |
| Artivion | $215M | Dec 31, 2025 |
| West Pharmaceutical Services | $203M | Dec 31, 2025 |
| NovoCure | $195M | Dec 31, 2025 |
| Ufp Technologies | $135M | Dec 31, 2025 |
| Orthopediatrics | $106M | Dec 31, 2025 |
Questions and answers
What is West Pharmaceutical Services's debt?
West Pharmaceutical Services had $203M of long-term debt on Dec 31, 2025, including the part due within a year, up 0.1% from $203M a year earlier.
Numbers as reported in West Pharmaceutical Services's annual and quarterly reports to the SEC (XBRL data). A year is the company's fiscal year that falls mostly in that calendar year; balances such as cash and debt are as of the date shown. Data only, not investment advice. Methodology